Literature DB >> 16858130

Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1).

Su-Ryang Kim1, Yoshiro Saito, Keiko Maekawa, Emiko Sugiyama, Nahoko Kaniwa, Hideki Ueno, Takuji Okusaka, Chigusa Morizane, Noboru Yamamoto, Masafumi Ikeda, Teruhiko Yoshida, Hironobu Minami, Junji Furuse, Hiroshi Ishii, Nagahiro Saijo, Naoyuki Kamatani, Shogo Ozawa, Jun-ichi Sawada.   

Abstract

Thirty-nine genetic variations, including thirty novel ones, were found in the human SLC29A1 gene, which encodes equilibrative nucleoside transporter 1, from 256 Japanese cancer patients administered gemcitabine. The found novel variations included -8,166G>A, -81,10A>G, -7,947G>A, -7,789T>C, -5,595G>A, -3,803_-3,783delTCGGGGAGGTGGCAGTGGGCG, -3,548G>C, -3,414G>A, -1355T>C, -34C>G, IVS1+141G>A, IVS1+260C>T, IVS1-82C>T, 177C>G, IVS3-6C>T, 564C>T, IVS8+44T>C, IVS8+90T>C, IVS8+97T>C, IVS8+131C>T, IVS8+169G>A, 933T>C, 954C>T, IVS11-52G>C, IVS11-46G>A, 1,288G>A, 1,641C>G, 1,703_1,704delGT, 1812C>T, and 1861C>T. The frequencies were 0.051 for IVS8+169G>A, 0.012 for -7,947G>A, 0.006 for IVS1+141G>A and 1,703_1,704delGT, 0.004 for -8,166G>A, -8,110A>G, -3,548G>C, -1,355T>C, -34C>G, IVS8+44T>C, and 1,812C>T, and 0.002 for the other 19 variations. Among them, 177C>G and 1,288G>A resulted in amino acid substitutions Asp59Glu and Ala430Thr, respectively. Using the detected polymorphisms, linkage disequilibrium analysis was performed, and 28 haplotypes were identified or inferred. Our findings would provide fundamental and useful information for genotyping SLC29A1 in the Japanese and probably other Asian populations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16858130     DOI: 10.2133/dmpk.21.248

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  14 in total

Review 1.  ABC transporters and their role in nucleoside and nucleotide drug resistance.

Authors:  Yu Fukuda; John D Schuetz
Journal:  Biochem Pharmacol       Date:  2012-01-20       Impact factor: 5.858

2.  Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.

Authors:  Taro Okazaki; Milind Javle; Motofumi Tanaka; James L Abbruzzese; Donghui Li
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

Review 3.  Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.

Authors:  Raphaël Maréchal; Anne Demols; Jean-Luc Van Laethem
Journal:  Drugs Aging       Date:  2013-03       Impact factor: 3.923

4.  Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.

Authors:  Jun Amaki; Makoto Onizuka; Ken Ohmachi; Yasuyuki Aoyama; Ryujiro Hara; Akifumi Ichiki; Hidetsugu Kawai; Ai Sato; Mitsuki Miyamoto; Masako Toyosaki; Shinichiro Machida; Minoru Kojima; Yukari Shirasugi; Hiroshi Kawada; Yoshiaki Ogawa; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2015-03-04       Impact factor: 2.490

5.  Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.

Authors:  Emiko Sugiyama; Nahoko Kaniwa; Su-Ryang Kim; Ryuichi Hasegawa; Yoshiro Saito; Hideki Ueno; Takuji Okusaka; Masafumi Ikeda; Chigusa Morizane; Shunsuke Kondo; Noboru Yamamoto; Tomohide Tamura; Junji Furuse; Hiroshi Ishii; Teruhiko Yoshida; Nagahiro Saijo; Jun-Ichi Sawada
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

6.  Cannabidiol As a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development.

Authors:  Gi Liou; Ab El-Remessy; As Ibrahim; Rb Caldwell; Ym Khalifa; A Gunes; Jj Nussbaum
Journal:  Curr Pharmacogenomics Person Med       Date:  2009-09

7.  Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.

Authors:  Motofumi Tanaka; Milind Javle; Xiaoqun Dong; Cathy Eng; James L Abbruzzese; Donghui Li
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

8.  Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer.

Authors:  Liang Li; Daniel J Schaid; Brooke L Fridley; Krishna R Kalari; Gregory D Jenkins; Ryan P Abo; Anthony Batzler; Irene Moon; Linda Pelleymounter; Bruce W Eckloff; Eric D Wieben; Zhifu Sun; Ping Yang; Liewei Wang
Journal:  Pharmacogenet Genomics       Date:  2012-02       Impact factor: 2.089

Review 9.  Genetic factors influencing cytarabine therapy.

Authors:  Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2009-10       Impact factor: 2.533

10.  Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers.

Authors:  Liang Li; Brooke L Fridley; Krishna Kalari; Gregory Jenkins; Anthony Batzler; Richard M Weinshilboum; Liewei Wang
Journal:  PLoS One       Date:  2009-11-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.